Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Experimental & Molecular Medicine ; : e27-2013.
Article in English | WPRIM | ID: wpr-119450

ABSTRACT

Wnt5a is a ligand that activates the noncanonical Wnt signaling pathways (beta-catenin-independent pathways). Human neutrophils expressed several Wnt5a receptors, such as Frizzled 2, 5 and 8. Stimulation of human neutrophils with Wnt5a caused chemotactic migration and the production of two important chemokines, CXCL8 and CCL2. CCL2 production by Wnt5a was mediated by a pertussis toxin-sensitive G-protein-dependent pathway. Wnt5a also stimulated the phosphorylation of three mitogen-activated protein kinases (MAPKs: ERK, p38 MAPK and JNK) and Akt. Inhibition of ERK, p38 MAPK or JNK by specific inhibitors induced a dramatic reduction in Wnt5a-induced CCL2 production. Supernatant collected from lipopolysaccharide-stimulated macrophages induced neutrophil chemotaxis, which was significantly inhibited by anti-Wnt5a antibody. Our results suggested that Wnt5a may contribute to neutrophil recruitment, mediating the inflammation response.


Subject(s)
Animals , Humans , Mice , Activating Transcription Factor 2/metabolism , Cell Separation , Chemokines/biosynthesis , Chemotaxis/drug effects , Culture Media, Conditioned/pharmacology , Extracellular Signal-Regulated MAP Kinases/metabolism , GTP-Binding Proteins/metabolism , JNK Mitogen-Activated Protein Kinases/metabolism , Lipopolysaccharides/pharmacology , Macrophages/drug effects , NF-kappa B/metabolism , Neutrophils/cytology , Pertussis Toxin/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Wnt/metabolism , Type C Phospholipases/metabolism , Wnt Proteins/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
2.
Experimental & Molecular Medicine ; : 216-222, 2010.
Article in English | WPRIM | ID: wpr-203591

ABSTRACT

Growth factor stimulation induces Y783 phosphorylation of phosphoinositide-specific PLC-gamma1, and the subsequent activation of this enzyme in a cellular signaling cascade. Previously, we showed that a double point mutation, Y509A/F510A, of PLC-gamma1, abolished interactions with translational elongation factor 1-alpha. Here, we report that the Y509A/F510A mutant PLC-gamma1 displayed extremely high levels of Y783 phosphorylation and enhanced catalytic activity, compared to wild-type PLC-gamma1, upon treatment of COS7 cells with EGF. In quiescent COS7 cells, the Y509A/F510A mutant PLC-gamma1 exhibited a constitutive hydrolytic activity, whereas the wild-type counterpart displayed a basal level of activity. Upon treatment of COS7 cells with EGF, the Y783F mutation in Y509A/F510A PLC-gamma1 (Y509A/F510A/Y783F triple mutant) cells also led to an enhanced catalytic activity, whereas Y783F mutation alone displayed a basal level of activity. Our results collectively suggest that the Y509A/F510A mutant is more susceptible to receptor tyrosine kinase-induced Y783 phosphorylation than is wild-type PLC-gamma1, but no longer requires Y783 phosphorylation step for the Y509A/F510A mutant PLC-gamma1 activation in vivo.


Subject(s)
Animals , Rats , Amino Acid Substitution/drug effects , COS Cells , Chlorocebus aethiops , Enzyme Activation/drug effects , Epidermal Growth Factor/pharmacology , Hydrolysis/drug effects , Mutant Proteins/metabolism , Phosphatidylinositols/metabolism , Phospholipase C gamma/genetics , Phosphorylation/drug effects , Phosphotyrosine/metabolism , Point Mutation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL